标签： 上海龙凤

It runs in the family grabs the market, a new prospect of domestic production in mazda 6.

　　[Information] The new generation travel version has been officially rolled off the production line in Yamaguchi Prefecture, Japan, and the off-line of this car means that the new mazda 6 will officially start mass production. A new generation of mazda 6 will also be made in Mazda in the future. According to Tian Qingjiu, deputy general manager of FAW Mazda, a new generation of mazda 6 will be sold together with the old mazda 6 next year. What will happen to the sales in it runs in the family and whether there will be any changes after the new generation of mazda 6 is made in China? We will analyze them one by one in this article.

Home of the car

　　● The old mazda 6 is still the main sales model-cost-effective.

　　From the sales volume of mazda 6 we collected, we can see that the sales volume of the old mazda 6 in 2010 was 94,369, and that of the old mazda 6 in 2011 was 91,358. By the first half of this year, the sales volume of the old mazda 6 was 38,482 vehicles. Compared with Ruiyi’s sales of 8,824 vehicles and 1,361 vehicles, the sales of the old mazda 6 in the first half of this year accounted for 76.33% of FAW Mazda’s sales share. Such a high proportion shows the importance of the old mazda 6 to FAW Mazda’s sales.

Mazda FAW Mazda mazda 6 2012 2.0 automatic ultra-luxury model

　　Last week, the 2012 mazda 6 went on the market, and its terminal price has dropped to 135,800 yuan. This price is no different from that of a mainstream compact car. The low price, dynamic appearance and good handling make the old mazda 6 have a very good cost performance, which is also the key for the old mazda 6 to become a pillar product of FAW Mazda.

Home of the car

　　In order to avoid internal consumption and overlapping positioning between products after the new generation of mazda 6 is listed, we guess that the prices of Ruiyi and the old mazda 6 will be adjusted accordingly in the future. The price range of Ruiyi will drop to 150,000-200,000 yuan, while the old mazda 6 will continue to drop to 100,000-150,000 yuan.

　　● Ruiyi-the advantages of the model are not obvious and the positioning is vague (the power is not strong enough and the movement is not thorough)

　　Compared with the sales volume of the old mazda 6, Ruiyi’s sales volume is not ideal, with 43,082 vehicles in 2010, 31,018 vehicles in 2011 and only 10,327 vehicles in the first half of this year. It can be seen that the sales volume of Ruiyi has shown an obvious downward trend year by year. Compared with other mainstream at the same price, Ruiyi’s sales are really not very good. So why is Ruiyi’s sales so low? Our conclusion is that the domestic medium-sized car consumers have limited recognition of sports medium-sized cars at present.

Mazda FAW Mazda Ruiyi 2012 2.0 Deluxe Edition

Home of the car

　　We have done a survey on consumers’ purchase intention in car home. When consumers buy medium-sized cars, the brands and prices are the most concerned. In the case of similar brands and prices, people tend to pay more attention to appearance, space and power, which are the three most important indicators for evaluating domestic medium-sized cars horizontally at present. In terms of appearance, the two main uses of consumers who generally buy medium-sized cars are home or business, so whether the appearance of a medium-sized car is stable or not has become one of the criteria for people to choose medium-sized cars. Ruiyi’s sporty design is obviously not as stable as other medium-sized cars, which also makes many medium-sized car consumers turn their attention to other brands.

Mazda FAW Mazda Ruiyi 2010 Coupe 2.5 Extreme Edition

　　◆ Sports positioning, but the power is not strong enough

　　I still remember the sportiness and maneuverability that Ruiyi emphasized in the publicity. It can be said that Ruiyi has some maneuverability, but the sportiness is probably worse. This is because Ruiyi, which is located in motion, lacks advantages in power. In the face of direct injection from European and American rivals, Ruiyi’s 147-horsepower 2.0L engine and 169-horsepower 2.5L engine really lack advantages. This also makes Ruiyi’s sportiness discounted. It is true that after many fans and media tests, Ruiyi’s chassis handling is highly evaluated, but the power is not strong enough, but it is always the shortcoming of Ruiyi.

Mazda FAW Mazda Ruiyi 2010 Coupe 2.5 Extreme Edition Mazda FAW Mazda Ruiyi 2010 2.0 Deluxe Edition

　　◆ Lack of price advantage, compared with the same price range of medium-sized car space is not enough.

　　The price range of 2012 Ruiyi is 179,800-239,800 yuan, and most of the medium-sized cars in the same price range have obvious space advantages. The Ruiyi 2725mm seems a little too conservative in the era when the wheelbase of medium-sized cars is getting longer and longer. We can look at the wheelbase of our competitors in the same price range as Ruiyi: 2800mm, 2775mm, 2737mm, 2795mm and 2795 mm. These opponents also have a good appearance and even better handling, but also have a good space performance. The short wheelbase of Re-Rui Wing directly leads to the general performance of Re-Rui Wing space, which affects the ride comfort. It seems that Ruiyi is a car on the surface, but actually it has become a Volkswagen car with a small audience compared with its competitors for the above reasons.

Comparison of Body Parameters between Ruiyi and Competitors 　 Wheelbase (mm) Body size (mm) Raptor 2725 4755*1795*1440 Accord 2800 4960*1845*1480 sounds of nature 2775 4850*1795*1475 Regal 2737 4830*1856*1484 Sonata 2795 4820*1835*1475 K5 2795 4845*1830*1460

Mazda FAW Mazda Ruiyi 2009 2.5 Extreme Edition

　　◆ Future positioning-the price may drop to 150,000-200,000 yuan.

　　With the new mazda 6 made in the future, in view of the fierce competition in the domestic medium-sized car market, the new mazda 6 will be similar to its competitors, and the estimated price range will be between 180,000 yuan and 250,000 yuan, so some price ranges will inevitably overlap with Ruiyi. In order to avoid internal friction, Ruiyi is bound to give up part of the price range to a new generation of mazda 6. It is estimated that the price range of Ruiyi will be around 150,000-200,000 yuan.

　　Editor’s note:At present, in the domestic medium-sized car market, appearance, space, power and price have become the main factors that determine whether consumers buy or not. Consumers’ inherent impression of medium-sized cars still exists in stability and comfort, while positioning and designing Rui Wing, which is more athletic but lacks space and motivation, is somewhat embarrassing. Consumers who pursue sports will turn to other brands because their motivation is not strong enough. The same lack of wheelbase and space makes Ruiyi have no confidence in facing a number of mainstream medium-sized cars. From the situation of Ruiyi, we can see that the domestic sports medium-sized car still cannot become the mainstream model at present, which is also reflected from the same positioning.

10 giant pandas collectively appeared in Nanjing on National Day, and ＂Panda Powder＂ at home and abroad visited them in groups.

　　China news agency, Nanjing, October 4 (Reporter Zhu Xiaoying) "The panda is coming!" "Hello, panda!" Amid cheers and photos, giant pandas are either "strolling" or playing "splashing" in people’s attention. On this National Day, 10 giant pandas who just settled in Nanjing made a collective appearance. A large number of "panda powder" groups at home and abroad came to visit.

　　"After a short adjustment, they are all in good condition when they arrive at their new home," Jiang Hao, deputy general manager of Nanjing Ziqinghu Wildlife World, told reporters on the 4th.

Data map: The giant panda grabbed the "rice basket" and seemed to express "Where is mine?" Photo by Zhu Xiaoying

　　In order to open up a new breeding base for giant pandas in Jiangsu, on August 28th this year, 10 giant pandas from China Giant Panda Protection and Research Center moved to Ziqinghu Tourist Area in Tangshan, Nanjing.

　　These 10 pandas are 6 males and 4 females, mostly in "young adults". Six of them are "returnees" born in Austria, Malaysia and the United States. Fu Hu, Fu Bao, Fu Feng and Fu Companion born in Sch? nbrunn Zoo in Vienna, Austria, are brothers and sisters, among which Fu Feng and Fu Companion are also the first surviving captive giant panda to raise twins. The other four are from Wolong base of China Giant Panda Protection Research Center and Bifengxia base of Ya ‘an.

　　On that day, "Fu Feng", "Fu Companion" and "Tuanzi" had a great time in the outdoor venue of the Panda Pavilion. The more "onlookers", the more "people are crazy", and they enjoyed tumbling, rolling and swinging. "Fufeng" and "Fuban" brothers and sisters "pick things up" and chase after each other, and "Tuanzi" even stands on their toys and interacts with tourists outside the glass window.

　　Some of the "Fu Hu", "Fu Bao" and "Wei Wei" who stayed indoors "feasted" on bamboo leaves, and some of them leaned back against the stump for a short rest. "These three pandas are not picky eaters, ‘ Appetite ’ Especially big. " Jiang Hao said.

Data map: After eating, the giant panda is in a daze and stares at the sky. Photo by Zhu Xiaoying

　　In the Panda Pavilion, Warm, who was born in Malaysia and has the most fans, still maintains a lazy and cold posture. I saw his limbs sticking to the ground, "keeping his eyes open" to recuperate. After a long time, he got up in "slow motion" and lay down with his arms outstretched holding the stump. Jiang Hao said that "warm" is the longest time in a day. If the distance that the breeder hands the bamboo leaves exceeds the length of its arm, it will "give up" the bamboo leaves in disgust and continue to be in a daze.

　　The lovely giant panda attracts many tourists, including "panda powder".

　　"During the National Day holiday, in order to see and photograph pandas, I booked an 8-day stay here." A tourist who has been photographing giant pandas for a long time told reporters. Jiang Hao also revealed that Malaysian "fans" who made a special trip to visit "Warm" have arrived in Shanghai and are on their way here.

Take you to see Beijing BJ60： all series of hybrid, battery life or more than 1000km

The launch of the tank series has aroused consumers’ pursuit of hard-line SUVs. The success of the Tank 300 and Tank 500 has also made many car companies see the hot spots. Recently, BAIC officially released the official map of the Beijing BJ60. The new car is positioned in a medium and large SUV, equipped with a hybrid system, with a battery life of over 1000km. Its competitors will target models such as the Tank 500 after its launch. Next, let’s take a look at the overall performance of this car.

From the design of the front face, the BJ60 still continues the family design language, the grille is still a five-hole design, and it is equipped with U-shaped LED light strips as an embellishment. The four-point headlights on both sides are matrix design, which looks to have a certain degree of recognition. The black decorative lines below are straight, and the two sides are also equipped with LED daytime running lights. After the overall lighting is lit, the front face is more recognizable at night.

The body lines are relatively simple, which is different from its BJ40. The new car still retains certain family car attributes on the basis of maintaining the hard style. The overall design of the body is similar to that of the Land Cruiser, Overbearing, Tank 500 and other models. The three-section window design widens the visual length of the body, and the raised design is adopted at the eyebrows, which improves the three-dimensional sense of the body. In addition, the size of the new car is 5020/1955/1925mm, and the wheelbase is 2820mm.

The rear of the car is a spare tire rear-mounted shape, so the tailgate adopts a lateral opening method. The taillights are affected by the spare tire and cannot be laid out in a large area, so a small square design is used, but the recognition is still relatively high. The lower exhaust adopts a hidden type, and the rear surround is embellished with silver, so the overall design is more in line with the style of hard-core off-road vehicles.

In terms of interior, the instrument panel of the BJ60 adopts a built-in layout, and the central control screen is a floating design. The center console shape is relatively flat, and the lines are mainly straight lines. Rectangular elements are used in many places in the car. In addition to the LCD instrument panel and the central control screen, the air conditioner trend, button area, stopper area, and central control trim are all rectangular designs. In addition, a large area of leather is used in the car, which is more comfortable in terms of touch.

It is expected that the size of the LCD dashboard will be 10.25 inches, and the size of the central control screen will be 12.3 inches. Officials have also said that the size of the dashboard of the new car will not be less than 10 inches, and the size of the central control screen will also be more than 12 inches. In addition, the square button below the central control screen of the car is not only the start button, but also can display the direction and time information. In addition, the car is equipped with more ambient lights, and the trim panel in front of the passenger is also equipped with a backlit ridge pattern.

In terms of power, the official said that the BJ60 will be equipped with a hybrid system, with an expected range of 1000km. The 100-kilometer speed increase time is also controlled at about 6 seconds. As a medium and large SUV, the acceleration performance is still relatively good. In addition, the new car is equipped with a time-sharing four-wheel drive, and the front and rear differential locks will also appear in the car. For example, the four-wheel drive system of the Tank 500 can switch between two-wheel drive and four-wheel drive modes at a speed of 80km per hour. What are the characteristics of the four-wheel drive system of the BJ60? It is still unknown.

Overall, the BJ60 is well-behaved in terms of design. From the information currently available, the car’s biggest feature is the hybrid system installed in the whole series. However, in recent years, BAIC’s performance in the overall market has not been satisfactory, especially in the hard-line off-road field that was once proud. I don’t know if the arrival of the new BJ60 will change. Let’s wait and see.

Maybach S-Class in Shanghai on sale! Special 1.3928 million, limited-time special offer

[Autohome Shanghai Promotion Channel] brings you an exciting news that the high-profile luxury sedan is having a grand promotion in Shanghai. At present, the maximum discount limit of this distinguished car has reached an astonishing 75,200 yuan, bringing consumers an unprecedented opportunity to buy a car. The starting price has been reduced to 1.3928 million yuan, which is an opportunity not to be missed. If you want to experience top luxury, or want to get more affordable friends in the car purchase process, please be sure to click the "Check Car Price" button in the quotation form to let the professional team provide you with more personalized discount details. Take advantage of the moment and enjoy the luxury experience brought by the Maybach S-Class.

上海地区迈巴赫S级特价出售！特价139.28万，限时特惠

As a symbol of luxury and dignity, the Maybach S-Class’s exterior design condenses elegance and power. The front face is outlined by exquisite chrome trims to outline the atmospheric grille, which is like a sculpture of exquisite details to reflect the brand’s dedication to craftsmanship. Streamlined body lines combined with low body height show unparalleled luxury. The overall style is noble without losing a sense of sports, and every detail exudes Maybach’s unique understanding of the art of luxury cars.

上海地区迈巴赫S级特价出售！特价139.28万，限时特惠

The Maybach S-Class stands out for its impressive body size, with a length of 5470mm, a width of 1921mm, a height of 1510mm, and a wheelbase of 3396mm, creating an elegant and spacious ride. Its front and rear wheel tracks are 1655mm and 1683mm respectively, ensuring driving stability and handling performance. The smooth lines on the side of the car reveal a low-key luxury temperament. The tire size of 255/45 R19 is selected, which combines comfort and grip, and is paired with a unique wheel design to add a sporty and refined element to the overall appearance.

上海地区迈巴赫S级特价出售！特价139.28万，限时特惠

The interior design of the Maybach S-Class shows the perfect fusion of extreme luxury and technology. The luxurious leather steering wheel uses electric up and down + front and rear adjustment functions, which makes the grip feel delicate and accurate. The center console is equipped with a 12.8-inch large-size touch screen, with a clear interface and automatic speech recognition control system, which can easily control multimedia, navigation, telephone and air conditioning functions. The seats are made of top-of-the-line leather, and the seat cushions and backrests are fully ergonomically designed to provide front and rear adjustment, backrest adjustment, high and low adjustment, as well as electric leg rest and waist support to ensure a comfortable experience for drivers and passengers. In addition, the front seats are equipped with heating, ventilation functions, and power seat memory functions to provide a personalized ride environment for each passenger. The second row of seats also has multi-directional adjustment, including leg rests, to create a distinguished mobility space. Whether it is exquisite details or rich configuration, the Maybach S-Class shows its outstanding quality as a luxury sedan in the interior.

上海地区迈巴赫S级特价出售！特价139.28万，限时特惠

The Maybach S-Class is powered by a 3.0T turbocharged engine capable of delivering 380 horsepower and 500 Nm of peak torque. The engine is paired with a nine-speed manual transmission, ensuring smooth and responsive driving.

Summarizing the owner’s comments, the Maybach S-Class won his admiration for its atmospheric high-end appearance, excellent comfort and interior quality. Its excellent fuel economy, strong power performance and reasonable space design all made the owner praise it. The owner’s satisfactory feedback undoubtedly strengthened the Maybach S-Class’s excellent image as a luxury car.

The many ＂flavors＂ of large kiln drinks, which one do you like the most？

　　　Drinking beverages is one of everyone’s daily hobbies. There are many beverage companies, and the flavors of beverages are also different. Today, let’s take a look at the main products of National Soda Kiln Beverages, and which flavors will you pick?


　　With the precise implementation of brand positioning, Big Kiln Beverage builds a super sign of communication as the pioneer of "Big Soda", opens the market through 520mL glass bottle packaging Big Soda, converts the selling point into the explosive point of "Big Soda, Drink Big Kiln", and continuously strengthens the brand impression of consumers. With the blessing of "large capacity, shareable, and refreshing atmosphere", it has successfully won the favor of many consumers and successfully entered the circle. In terms of taste, Big Kiln Beverage’s juice soda is mainly based on three classic flavors, supplemented by new flavors, to meet the diverse needs of consumers.


　　"Big Kiln Guest" is a childhood memory that many people love. When you open the bottle cap and "poof", a "guest flavor" that combines the unique flavor of honey, fruit and carbonated drinks will fill the air, and it will feel full of bubbles. When you drink it in your mouth, the bubbles and fruit aroma burst in your mouth at the same time, and your senses will be instantly stimulated. "Big Kiln Orange Nuo" is full of orange flavor, maintaining the natural sweetness of the fruit itself. "Big Kiln Li Ai" is a rich lychee flavor, which brings a sweet and refreshing taste to the taste buds, and every bite can feel the vibrant lychee flavor. Big Kiln recently also launched a pineapple flavor, which is sweet and sour, juicy and fresh, with refreshing bubbles, a mouthful of satisfaction! It can be said that each flavor of the Dayao beverage juice soda series has its own unique characteristics and is very popular with consumers.


　　In addition, Dayao drinks focus on young, portable, and trendy style products have also carried out taste innovation, launching lime, frozen pear, and pineapple flavored juice soda. Dayao lime perfectly blends bubbles with lime, with a fresh taste and full of lime flavor; frozen pear is a specialty food in Northeast China, and it also has a unique flavor when combined with soda. Erbin’s frozen pear on the plate is not eaten, so it is better to have a bottle of Dayao frozen pear soda; pineapple flavored soda is sweet and sour, with fresh bubbles and refreshing, as well as dopamine color scheme, a bright spring happy drink!

　　It can be seen that the strength of Big Kiln Beverages in taste innovation cannot be underestimated. Big Kiln Beverages also launched 0 sugar series, fun soda sparkling water, small kiln fruit steam, Chayuanxiang juice gas tea, pomelo love honey pomelo gas tea, energy coffee, kiln fruit, etc., to build a four-category matrix of carbonated drinks, juice drinks, plant protein drinks and functional drinks to meet the diverse needs of consumers.

　　Consumer demand continues to change, and innovation in soda flavors will continue to evolve. According to Innova Market Insights, floral and nostalgic flavors with modern flavors are likely to resonate with consumers in 2024. 33% of consumers said they had looked for more floral flavors in the food and beverage category. Chamomile, peach blossom and honeysuckle are considered to be the fastest growing floral flavors. Will Big Kiln Beverages also introduce related new flavors? You can also look forward to it!

Women complain that Xiaomi SU7 has not delivered the painted Xiaomi car： relevant policies will be issued to solve it.

Recently, after the launch of Xiaomi SU7, it was sought after by many people. However, Ms. Mo from Shenzhen, Guangdong Province was upset because she bought the original version of Xiaomi SU7. Her car has not been received yet, but she was told that the car bumped during transportation and the paint fell off the front cover.

According to @ Leng Wen Video, on April 4th, in Shenzhen, Guangdong Province, Ms. Mo issued a document saying that she bought the original version of Xiaomi SU7 car, and when the car arrived, she was told that there was a bump in the transportation process, and a piece of paint was covered in front of the car, so she could only make up the paint and pay 5000 points (the purchasing power in Xiaomi Mall is equal to 500 yuan) and then deliver it normally.

After Ms. Mo said that she refused, the other party proposed a solution of compensation of up to 20,000 points, which did not support the replacement of a new car, and the deposit for returning the car could not be refunded. Ms. Mo refused again, and Ms. Mo insisted on replacing the new car.

For this matter, Xiaomi Automobile customer service said that it is impossible to replace a new car, and it will take a long time to reorder. You can negotiate with the delivery center and follow up with relevant policies to solve such problems.

The staff of Shenzhen Xiaomi Delivery Center said that there will be a person in charge of the delivery center to deal with the privacy of the owner.

In this regard, some netizens said that the collision of new cars is obviously a non-consumer responsibility, and Xiaomi Automobile only compensates for points. This after-sales service is too perfunctory!

Some netizens also said that Xiaomi’s mobile phone did a good job, but I didn’t expect such a mistake in the automotive field.

Source: @ 中中中中中, Red Star News

In the face of the ＂cliff-like＂ decline in the price of centralized mining, how to deal with the heart stent enterprises？

Sheng: the "past lives" of heart stent

Cardiac stent, also known as coronary stent, is a high-value consumable commonly used in percutaneous coronary intervention (PCI), which has the function of dredging arterial blood vessels and is recognized as a conventional treatment for cardiovascular diseases. Since the first generation of stents went on the market in 1997, the development of cardiac stents has gone through three stages, the first generation is the balloon expansion era, the second generation is the bare metal stent era, the third era is the drug-eluting stent era, and it is now moving towards the fourth generation of completely degradable stents. With the continuous evolution of materials, the performance is more and more optimized. The main features of each generation of cardiac stents are as follows:

Fig. 1 development of cardiac stent

At present, non-degradable drug eluting stent,DES) is still the mainstream choice for clinical application, and fully degradable stent is still in the early stage of product development and clinical application. At present, the mainstream cardiac stents in the market are still drug-eluting stents, and the market share has remained at around 99% since 2012, and balloons and bare metal stents have been completely replaced by them. Biodegradable stents (BRS) can be gradually absorbed in the body, which can significantly reduce the formation of stent thrombosis and restenosis, at the same time, it will not affect MRI and CT scanning, and also facilitate the re-intervention process. It is the main direction of stent research and development in the world, and has attracted extensive attention from medical device companies at home and abroad. At present, the fully degradable heart stents put into research and development are mainly divided into two categories: degradable metal materials and degradable polymer materials.

Fig. 2 Types of mainstream cardiac stents currently in use

(A) In recent years, the demand for cardiac stents has been increasing, and the scale has steadily increased.

1. The number of PCI interventions in China ranks first in the world, and the number of PCI interventions has increased by over 15% annually in recent five years.

From 2015 to 2019, the number of cases of percutaneous coronary intervention (PCI) in China increased steadily, with an average annual increase of 16.0%. Among them, the number of percutaneous coronary intervention (PCI) in China in 2019 was 1.03 million, ranking first in the world, with an increase of 12.6% compared with 2018. It is conservatively estimated that there will be nearly 1.2 million cases of percutaneous coronary intervention (PCI) in China in 2020.

Fig. 3 Trends of PCI operation volume in China from 2015 to 2020 (data source: analysis by Health Research Institute).

In 2020, the market value of heart stents in China is close to 17.5 billion yuan.

From 2015 to 2019, the number of cardiac stents implanted in China showed a steady growth trend year by year, with an annual growth rate of 15%-20%. In 2019, the number of cardiac stents implanted in China was 1.6 million. In terms of market value, the market value of heart stents in China increased from 9.75 billion yuan to 15.97 billion yuan from 2015 to 2019, with an average annual growth rate of 15.2%. It is estimated that the market value will be close to 17.5 billion yuan in 2020.

Fig. 4 Trend chart of cardiac stent implantation quantity and scale in China from 2015 to 2020 (data source: analysis by Health Research Institute).

(B) The "market just needs+policy orientation+technology promotion" troika escorts the rapid development of the cardiac stent industry.

1. The market just needs:The two major trends of younger coronary heart disease and aging population have once again "expanded" the cardiac stent market.

Younger coronary heart disease:Cardiovascular disease has become the number one health killer in the world, accounting for nearly 30% of the total global deaths. According to China Cardiovascular Health and Disease Report 2019, the number of cardiovascular patients in China reached 330 million, accounting for more than 45% of the deaths of residents, ranking first among all diseases. Among them, the number of patients with coronary heart disease has reached 11 million, with more than 3 million new patients each year and more than 1 million patients with sudden infarction. In addition, the younger trend of coronary heart disease (CHD) is increasing. According to a survey of cardiovascular diseases among more than 20,000 people in Shanghai, the number of patients with CHD accounts for nearly 30%, of which 27.0% are over 70 years old, 40.0% are 51-70 years old, and 33.0% are under 50 years old. CHD is no longer a "patent" for the elderly, and it is obese, stressful and stressful.

Figure 5 Proportion of cardiovascular disease population structure (data source: public information)

Aging:According to statistics, in 2019, the population aged 65 and above accounted for 12.6% in China. From the development trend, the population aging speed and scale in China are unprecedented. After 2022, China will enter a deeply aging society with a proportion of over 14.0%, a super aging society with a proportion of over 20.0% around 2033, and then it will continue to rise to 35.0% in 2060. The arrival of the era of deep aging will undoubtedly raise the "ceiling" of the heart stent industry.

Figure 6 Structural trend of population aging in China (data source: public information)

With the development of younger coronary heart disease and aging population, and considering the impact of centralized procurement on the price of cardiac stents and the improvement of people’s health awareness, the number of PCI operations per capita in China will be in line with that of developed countries in the future (the number of PCI operations per million population in China is 736, that in the United States is about 3,135, and that in Japan is about 2,047, which is 4.3 times and 2.8 times that in China, respectively). According to the extreme analogy method (referring to the number of PCI operations per million people in Japan, mainly considering that China and Japan are similar in race and incidence), it is estimated that the peak number of PCI operations will reach 2.87 million in the future. Considering the average number of stents implanted in PCI (about 1.5 stents/case), the corresponding peak number of cardiac stents implanted is about 4.3 million, which has a large long-term permeability and market space.

Fig. 7 Comparison of the number of percutaneous coronary intervention (PCI) between China and major developed countries (data source: analysis by Health Research Institute).

2. Policy orientation:Front-end encouraging innovation and end-collection specification help the market demand of cardiac stents to be released continuously.

In recent years, the state has launched a series of favorable policies for the medical device industry to support the rapid development of enterprises:

innovateEncourage the acceleration of the transformation and upgrading of medical devices, develop high-end interventional products such as fully degradable vascular stents, and stimulate the development of new cardiac stents market segments; Priority is given to the review and approval of qualified innovative medical devices. Under the promotion of innovation policy, the fully degradable polymer matrix drug (rapamycin) eluting stent system (NeoVas) independently developed by Lepu Medical and the fully degradable polylactic acid stent (Xinsorb) independently developed by Academician Ge Junbo of China Academy of Sciences have all entered the special approval procedures for innovative medical devices.

circulateFrom the national level to the provinces and cities, the centralized purchasing scheme of high-value consumables has been launched one after another, constantly rationalizing the price system of high-value medical consumables and improving the supervision and management of the whole process. In October 2020, coronary stents became the first batch of purchased varieties, and the national level started the collection of high-value medical consumables.

Table 1: Main policies related to high-value consumables such as cardiac stents from 2016 to present:

3. Technology promotion:The iterative upgrading of products and the improvement of interventional surgery level greatly enhance patients’ confidence and willingness to receive interventional therapy.

Iterative upgrade of products: cardiac stent has experienced the development from balloon expansion to drug-eluting stent, and the restenosis rate of stent implantation has decreased by nearly 20%, and the incidence of thrombosis in stent has decreased to about 1%, which effectively reduces the risk of complications for patients;

Improving the level of interventional surgery: China has successively established the training base of cardiovascular interventional diagnosis and treatment of the Ministry of Health and the national quality control center of PCI, and adopted a unified training model to carry out systematic training nationwide, and issued certificates after passing the examination, and carried out quality control and index monitoring on related work. In 2018, the mortality rate of interventional therapy for patients with coronary heart disease was 0.26%, far lower than that in the United States.

(III) Competition pattern: Domestic substitution in the cardiac stent industry has basically been completed.

After decades of development, the technical generation gap among major enterprises has gradually narrowed, and the industry pattern has been basically stable, mainly relying on the launch of new products to enhance market share. Judging from the competition pattern, the concentration of cardiac stent industry is high, and the market share of domestic drug stent products exceeds 70%, and the domestic substitution is basically completed. Among them, domestic brands such as Weichuang, Lepu and Jiwei rank among the top three, with a total market share of over 65%.

Figure 8 Market share of domestic cardiac stent brands in 2019 (data source: analysis by Health Research Institute)

In 2019, the revenues of cardiac stents (including balloons, catheters and other ancillary products) of minimally invasive medical care, Lepu medical care and Jiwei medical care were 1.83 billion yuan, 1.79 billion yuan and 1.74 billion yuan respectively, with growth rates of 33.0%, 26.7% and 24.9% respectively. As can be seen from the figure, cardiac stents of minimally invasive medical care showed a trend of "double high" in sales growth rate and market share.

Figure 9 Market share and revenue growth rate of cardiac stent head enterprises (data source: analysis by Health Research Institute)

Change: the national "group purchase" triggered a major change in the heart stent industry.

With the landing of the national heart stent collection, the "suicide" price reduction of enterprises has also brought infinite reverie to the future direction of the industry. Will the heart stent industry under centralized procurement be a "broken wrist" or a "rescue" in the future? Is it "price for quantity" or "innovation and transformation"?

(A) the change in scale

Centralized procurement of cardiac stents directly affects the purchase price. According to the recent centralized purchasing list published by the Medical Insurance Bureau, the number of intentional purchases in the first year exceeded 1.07 million, involving 27 products. Based on the published average price quoted by the winning bidder (1682 yuan/piece) and the amount of coronary stents implanted in 2021, the market value in 2021 is about 3.19 billion yuan. It should be emphasized that the market value forecast here does not consider the impact of the decline in centralized purchasing price on the improvement of patients’ willingness to operate.

Fig. 10 Market value forecast of cardiac stent in 2021 (data source: analysis by Health Research Institute)

According to the previous estimation of the amount of cardiac stent implantation in China, when the amount of PCI operation per 100 people reaches the Japanese level, the peak amount of cardiac stent implantation in China is 1400 x 2047 x 1.5 = 4.3 million. According to the heart stent of 1682 yuan/piece (the average price of centralized procurement), the corresponding market value of heart stent is 7.23 billion yuan:

Fig. 11 Market value of China cardiac stent corresponding to peak value (data source: analysis by Health Research Institute)

From the above analysis, it can be seen that under the influence of centralized procurement policy, the market value of heart stents in China in the next 1-3 years is expected to be in the range of 3-7 billion yuan.

How much money can patients save after centralized collection?

As we all know, the "floor price" of centralized purchasing has a great influence on patients who are unwilling to undergo interventional surgery because of the high price. This paper analyzes the payment situation of patients before and after centralized purchasing (according to the conventional reimbursement policy):

Fig. 12 Comparison of patients’ self-funded amount before and after centralized purchasing (data source: analysis by Health Research Institute)

As can be seen from the above figure, according to the same reimbursement policy, the out-of-pocket medical expenses of patients decreased from 6520 yuan to 308 yuan before and after centralized purchasing, and the personal burden was only 4.7% of the original, which greatly eased the economic burden.

(2) Changes in business

In addition to the industry scale being affected, the business tentacles of heart stent enterprises will also be adjusted:

1. Stent market: form a low-cost medical insurance centralized procurement market+off-standard non-medical insurance high-end alloy stents+medical insurance stainless steel stents+non-medical insurance ultra-high-end degradable stents.

In the short term, the market of cardiac stent products will form a pattern of low-cost medical insurance centralized procurement market+off-standard non-medical insurance high-end alloy stent+medical insurance stainless steel stent+non-medical insurance ultra-high-end degradable stent:

On the one hand, from the current attitude of centralized mining, bare metal stents are not included in the list of centralized mining, and the price of stainless steel stents will be under pressure due to the price reduction of centralized mining in the short term, and the price inversion with alloy stents will not last long; In the long run, stainless steel stents are not as good as alloy stents in terms of support and passability. As a more backward technology than Co-Cr alloy and Pt-Cr alloy, stainless steel stents will face marginalization in the future. However, in view of the fact that the use of stainless steel coronary stents still accounts for about 40% of the market share in 2019, stainless steel coronary stents will be coasting for a period of time in the future.

On the other hand, with the continuous promotion of cardiac stent collection, the trend of differentiation and stratification of end patients will become more obvious, and the group of self-paid high-priced stents may expand. Degradable stents and metal stents belong to two price bands, so it is impossible to talk about the market share substitution after the huge change of centralized purchasing price. Moreover, the proportion of consumables in the cost of PCI surgery has further decreased, and the audience’s marginal willingness to pay for innovative products is likely to increase. In the medium term, the development rhythm of fully degradable stents will continue to be stable, in order to get as much clinical data as possible, enhance the recognition and acceptance of products by more experts, doctors and patients, and enhance the high-end market share.

Figure 13 Future product layout of cardiac stent

2. Business reshaping: cultivate and expand new medical formats around the cardiovascular field, and make a forward-looking and diversified layout.

On the one hand, it conforms to the latest concept of "intervention without implantation" of the current interventional instruments, and extends upstream and downstream around the coronary intervention chain:

Product chain: the price reduction of metal stents will be the norm in the future, and the fully degradable stents and drug balloons with "intervention without implantation" will become the core of future development. Facing the policy impact of centralized stent mining, it will be an effective hedging means to extend the layout of coronary intervention chain. In addition to completely degradable stents, a new generation of drug-coated balloon (DCB) has also become the core of future development under the new concept of "interventional non-implantation". The data shows that the usage of drug-coated balloons in some hospitals or individuals in Europe has reached 50%-90% of all PCI, and Japan has reached 4,000 per month, accounting for about 15% of Japanese PCI. In addition, auxiliary consumables (balloons, catheters, guide wires, etc.) related to coronary intervention will also become the profit growth point that enterprises pay attention to.

Technical service chain: The further decline in the proportion of consumables in the cost of PCI surgery has prompted enterprises to speed up the layout of medical services and health management sectors. Conditional enterprises will cooperate with primary hospitals to provide equipment consumables, drugs and medical technical services needed for interventional diagnosis and treatment, and promote the grassroots promotion and popularization of new interventional technologies, which will become an important exploration for coronary intervention enterprises to face the centralized procurement of high-value consumables.

On the other hand, the centralized procurement of cardiac stents has prompted enterprises to expand from coronary intervention to peripheral intervention, and continuously enrich their product lines:

Make full use of enterprise stent balloon design and precision manufacturing platform technology, constantly innovate and develop, expand the company’s products from coronary intervention to peripheral intervention, continuously enrich the cardiovascular disease product line, and concentrate on improving the company’s marketing network structure to cope with market risks brought about by policy uncertainty.

Figure 14 Possible business development direction of cardiac stent enterprises under the background of centralized procurement

(C) changes in the market

Under the general trend and background of medical insurance fee control and national centralized procurement, it has a great influence on the competition pattern of domestic medical industry. Medical device enterprises will face more fierce market competition, as well as the realistic problems of product prices and product profit margins falling sharply. For the leading enterprises in the industry, although they can seize more market share by winning the bid at a low price, the problem of shrinking scale and declining profit rate cannot be underestimated.

In the foreseeable future, the scope of domestic medical insurance control fees will only increase, so as to more effectively reduce the pressure of medical insurance expenditure, reduce the prices of drugs and devices and benefit the people’s livelihood. In addition, the situation in the field of devices may appear in the previous pharmaceutical field, and importers may take more aggressive quotations to seize the domestic market after they are familiar with the rules.

For domestic cardiac stent enterprises, facing the policy risks of centralized procurement and medical insurance control, they need to seize the domestic share, turn their attention to the international market and participate in the international market competition. In fact, domestic heart stent head enterprises have also started the international strategic layout, among which minimally invasive medical care, Lepu medical care and Lan Fan medical care are typical representatives.

Turn: Transforming into a strategic choice for heart stent enterprises to overtake in corners.

In the face of major changes in the national medical device policy, cardiac stent enterprises actively predict the development trend, plan ahead, and focus on developing products and new businesses related to centralized procurement while strengthening product technology innovation. For domestic heart stent enterprises, what transformation layouts have been made at present? What is the possible key direction of development in the future?

(1) Adjust the business strategic map and form a multi-sector support system.

1. Diversification of business lines-minimally invasive medical treatment

Through business diversification, we will continuously broaden profit points and enhance comprehensive competitiveness. In recent years, Minimally Invasive Medical Devices Co., Ltd. (hereinafter referred to as "Minimally Invasive Medical") has continuously enriched its product line and expanded its business field through outreach acquisition and endogenous development. Products gradually changed from early cardiovascular stents to diversified business systems covering cardiovascular intervention, orthopedic medical devices, heart rate management (pacemaker), arterial and peripheral vascular intervention, and nerve intervention products.

In 2019, the business revenue was 5.55 billion yuan, of which 33.4% came from cardiovascular interventional products, 29.3% from orthopedic medical devices, 26.3% from heart rhythm management business, 6.1% from arterial and peripheral vascular interventional products, and 3.5% from neurological interventional products. In 2012, the revenue of minimally invasive medical cardiovascular interventional products (stents) accounted for 83.8%.

Figure 15 Comparison of the proportion of minimally invasive medical business segments in 2012 and 2019 (data source: minimally invasive medical annual report)

2. Product line "from one to four", and build a platform business model of "equipment+medicine+medical service+new medical care"-Lepu Medical.

Lepu (Beijing) Medical Devices Co., Ltd. (hereinafter referred to as "Lepu Medical"), as one of the earlier enterprises engaged in the research and development of cardiovascular interventional medical devices in China, has been accelerating the business integration, optimization and layout in recent years, and has developed from a single stent business in 2013 to four business segments covering "devices+drugs+medical services+new medical care" at present, with the goal of building a platform-based business model around the whole life cycle service for cardiovascular patients.

Figure 16 Main contents of each business segment of Lepu Medical

Dual track of medical devices and medicines: In terms of revenue, the revenue of Lepu Medical in 2019 was 7.80 billion yuan, a year-on-year increase of 22.6%. Among them, the medical device sector achieved operating income of 3.62 billion yuan, accounting for 46.4%, and the pharmaceutical sector achieved revenue of 38.5%, accounting for 49.4%. Among them, the revenue of coronary stent system only accounts for 20% of the total revenue of Lepu Medical. In addition, the market share of the company will be directly increased after winning the bid, and the negative impact of centralized procurement is relatively limited.

Figure 17 Revenue Ratio of Lepu Medical in 2019 (Source: Lepu Medical Annual Report)

3. "Health protection+medical equipment" two-wheel drive-Lan Fan Medical

Lan Fan Medical Co., Ltd. (hereinafter referred to as "Lan Fan Medical") is a leading enterprise in the field of medical gloves in the world, accounting for 22% of the global market. In 2018, it successfully acquired the fourth-ranked cardiac stent company in the world, Singapore Baisheng International Group, and realized its layout in the field of medical devices. Subsequently, Lan Fan Medical implemented the "A+X" industrial strategy, and set up four business divisions with a total of seven tracks:

Figure 18 Layout of Lan Fan Medical Industry

At present, Lan Fan Medical has two business series products, namely health protective gloves and heart stents, which are continuously extended to the whole chain of emergency care, cardiovascular and cerebrovascular diseases, forming a multi-business sector collaborative model combining low-value, medium-value and high-value consumables products, with complementary modes and risk hedging. In 2019, Lan Fan Medical achieved a revenue of 3.48 billion yuan, of which the revenue of health protective gloves was 1.68 billion yuan, accounting for 48.3%, and the revenue of cardiac interventional devices (including self-produced and agents) was 1.74 billion yuan, accounting for 50.0%.

Figure 19 Revenue Ratio of Lan Fan Medical in 2019 (Source: Lan Fan Medical Annual Report)

(2) Expand the cardiovascular product chain and form a diversified ecological closed loop.

1. Strategic positioning of big heart-minimally invasive medical treatment

Based on its own existing technology and platform, minimally invasive medical care constantly lays out big heart tracks: coronary heart disease, arrhythmia, structural heart disease and heart failure.

Development contextMinimally invasive medical care started from coronary stent, then cut into radiofrequency ablation, and then extended to pacemaker business. Later, with the further development of interventional technology, structural heart disease entered the era of minimally invasive surgery, and minimally invasive medical care opened up the technical path of completing heart valve replacement by interventional method (representative product VitaFlow transcatheter aortic valve system). Compared with these business units with mature products, Minimally Invasive has begun to "plan the layout" of the treatment solution for heart failure, which is also an important pawn for the future layout of Minimally Invasive and the key to completing the closed loop of the big heart business.

2. Optimize iterative coronary medical devices, enrich and innovate the implantable product line-Lepu Medical.

Lepu Medical has built a rich product group of devices in the cardiovascular field:

1) Accelerate the industrial chain matching of coronary intervention devices. In 2019, Lepu medical coronary stent products achieved operating income of 1.53 billion yuan, a year-on-year increase of 23.3%; Supporting auxiliary consumables (balloon catheter, guide wire, etc.) realized an operating income of 260 million yuan, up 51.0% year-on-year. Under the background that most of the auxiliary PCI interventional materials such as balloon catheter guide wire are monopolized by foreign capital, Lepu Medical is the only R&D and manufacturing enterprise in China that can provide all the consumables for coronary intervention. At present, more than ten necessary consumables such as pre-expanded and post-expanded balloon catheter, PTCA guide wire, guide catheter, contrast guide wire, contrast catheter, sheath, Y valve, triple tee, pressure extension tube, pressure pump, ring handle syringe, pressure sensor and hemostasis compressor have all been mass-produced.

2) Coronary balloon products and NeoVas bioabsorbable stents are expected to form new growth points. In February 2019, NeoVas, an international second-generation bioabsorbable drug stent independently developed by Lepu Medical, was approved for listing in China, and opened a new era of PCI technology "intervention without implantation". In July 2019, the first-generation coronary balloon was approved by GMP for the first time. Three products of the second-generation drug balloon series are about to start clinical trials, and the third-generation rapamycin drug balloon technology has made breakthrough progress, and animal experiments will be carried out soon.

In addition, in recent years, Lepu has actively developed peripheral products of degradable and drug balloons based on the Group’s coronary stent and balloon platform technology, and its business scope has expanded from coronary intervention to peripheral intervention.

3. Layout of coronary artery, valve, nerve intervention and peripheral intervention-Lan Fan Medical.

At the time when the medical device industry entered the golden period of development, Lan Fan Medical continuously accelerated the overall layout of cardiovascular and cerebrovascular devices based on the leading edge of Baisheng International Cardiology Department:

In the field of coronary intervention: all kinds of stent products produced by Singapore Baisheng International are sold to more than 90 countries and regions around the world, with a sales volume of 400,000. At present, BioFreedom, a drug-coated stent of BA9? without polymer carrier, has been introduced into European and Japanese markets, and it is expected to be listed in the United States and China in the near future. From the perspective of stent technology, the upgrading of technology is still the theme of stent industry and the driving force of sales growth. The increase in the proportion of high-end stents such as BioFreedom and Excrossal, as well as the development of foreign markets, have helped to enter the new product bonus period. In addition, taking the cardiac stent as the fulcrum, we will enrich, expand and improve the product line combination related to PCI surgery, such as contrast guide wire, contrast catheter, guide wire, guide catheter, pre-expanded balloon, post-expanded balloon, puncture needle, arterial sheath and pressure extension tube.

Cardiovascular related product lines: Apart from coronary artery, valve, nerve intervention and peripheral intervention are also the tracks that Lan Fan Medical keeps cutting in. By continuously expanding and expanding related product lines such as valve, nerve intervention, peripheral intervention and drug balloon, the competitiveness of product portfolio will be enhanced. The capital is undoubtedly the quickest way for Lan Fan Medical to broaden the track. In June, 2020, Lan Fan Medical acquired the fifth manufacturer of TAVR in the European market. NVT’s main business is the research and development, production and sales of interventional valves for structural heart disease. Through the acquisition of TAVR, a gold track for medical devices, NVT officially entered the field of minimally invasive interventional structural heart disease therapy with broad prospects.

(C) the implementation of internationalization strategy to enhance the international market share of products.

1. Actively deploy the global mainstream market-minimally invasive medical care.

Since 2014, minimally invasive medical care has set its sights on overseas and accelerated the export of China native coronary stents to overseas markets. In 2019, the overseas business of minimally invasive medical drug-eluting stents achieved revenue of 160 million yuan, a year-on-year increase of 72.4%. Sales in 25 countries or regions and registration certificates in 13 countries or regions. Among them, Firebird2TM’s overseas revenue increased by 186.9% year-on-year, FirehawkTM’s revenue increased by 54.6% year-on-year, and it has been sold in several major European countries. In addition, the group has also submitted the application for registration of FirehawkTM stent to the Japanese medical device review and approval authority, and actively deployed the global mainstream market.

Figure 20 Sub-regional Income Ratio of Minimally Invasive Medical Care in 2019 (Source: Minimally Invasive Medical Annual Report)

2. Establish an international business department to increase the market share of international innovative products-Lepu Medical.

Lepu Medical put internationalization on the agenda after the first round of domestic drug collection in 2018, and proposed to further increase the market share of international innovative products. At present, the original foreign trade business and departments of all subsidiaries have been integrated, and the international business department has been established to strengthen the international influence on the upstream and downstream of the medical industry chain in the cardiovascular field. Explore the possibility of setting up R&D centers and production bases overseas. Overseas R&D centers have been planned to accelerate the clinical registration of innovative products (degradable stents, TAVR3.0, renal artery ablation, artificial intelligence ECG and artificial intelligence monitoring) in the world.

It is reported that Lepu Medical’s business revenue from abroad in the first half of 2020 was 870 million yuan, an increase of 320 million yuan compared with the whole year of 2019. Guo Tongjun, senior deputy general manager and secretary of the board of directors of Lepu Medical, said at the reception of listed companies that the company’s overseas market target remains unchanged, and the proportion of overseas market revenue will continue to increase to 20%-30% in the next 3-5 years.

Figure 21 Lepu Medical Internationalization Strategic Measures

summarize

National centralized procurement is not only a reshuffle of the cardiac stent industry, but also an impetus to the cardiovascular segmentation field. Heart stent enterprises still have a long way to go, but whether they are facing the "change" of the industry calmly or actively responding to the "turn" of the industry, there are undoubtedly two ways to go: First, strengthen the technological innovation and product iteration of heart stents in order to obtain new user markets; The second is to realize business diversification and risk hedging with the heart stent as the fulcrum.

Comment immediately ｜ Suzhou Zoo dug up the old version of A Dream of Red Mansions？ Why do old rumors become fine？

In the past few days, you have probably seen such a "big news" in your circle of friends: On February 27, 2018, the first shovel of the renovation project of Shihushan in Suzhou Zoo accidentally opened an ancient tomb. Among more than 300 cultural relics unearthed, the most legendary complete version of A Dream of Red Mansions was named "A Trial Evaluation of the Addition and Deletion of Wu’s Stone Story" by the academic circles, and many mysteries of the Red Mansion for hundreds of years were solved! Hu Shi, Zhou Ruchang and other Redology masters worked so hard to build the Redology Building, and suddenly collapsed!
It’s the old copy of The Red Mansion unearthed, and it’s the collapse of the redology building. Even the time and place are so obvious that netizens don’t believe it. This article has already won 100,000+.
However, in fact, the so-called "Wu’s Stone Story" is an old rumor for 10 years. In 2008, "He Lili" (pseudonym, male, junior high school education) handed over the so-called "Wu’s Stone Story" to Liu Junjun to upload it to the Internet, and the rumor began. "He Lili" said: Grandparents accidentally got a copy of A Dream of Red Mansions that year; Only He Lili has ever read this set of books and copied the contents with his cousins. then what Such a precious codex disappeared, leaving only the electronic version of "Wu’s Stone’s Addition and Deletion Trial Review" uploaded by "He Lili".
"He Lili" claimed that this manuscript was written in the year of Guiyou in the lunar calendar, that is, in 1753 AD, one year earlier than the female parent of Jiaxuben, the earliest banknote copy of A Dream of Red Mansions discovered so far in the red circle! Is it subversive enough? Even more subversive, they claimed that the author of the book was Wu Meicun in the late Ming and early Qing Dynasties, not Cao Xueqin! So A Dream of Red Mansions has to be called "Wu’s Stone"!
This low-level rumor can’t be logically consistent. It has been said to be an ancient manuscript, but several netizens kept revising it. By the time Guiyouben released the so-called "third anniversary edition" online edition in 2011, the content had been changed to "Fan Sixth Edition" (original text). Several authors who faked together finally even set up their own businesses and compiled several versions of Gui You Ben. Some authors wrote anonymous, while others wrote Cao Xueqin.
The writing of "Wu’s Stone Story" is vulgar, and even the modern "humane" saying of "fellow villager" and "help us for the sake of understanding" appears in the article; The plot is even more absurd and vulgar, and netizens call it "spicy eyes": Mrs. Wang, who believes in Buddhism, wants Baoyu to marry a nun, Baoyu becomes an adulterer, Sister Lin becomes an armed leader and leads slaves to defend the Grand View Garden, and Baochai seduces Baoyu …
When popular science professionals disdain to refute it, such information garbage is occupying people’s brains and occupying valuable information channels. On February 27th this year, Guangming Daily published a report on "The Collapse of Wu’s Stone".
However, Guangming Daily has just started a rumor, and now the rumor has put on a new vest: "On February 27th, the renovation project of Shihushan in Suzhou Zoo was dug up …", The rumor maker deliberately chose such a day, which can be regarded as naked provocation and fooling. The media sentenced it to death on that day, and it chose to be resurrected with blood on that day.
A netizen with junior high school education pretended to be a female netizen, and wrote such a "Stone Story" directly with the keyboard and posted it on the Internet. The plot was spicy and the text was vulgar, but just say: This is the "Dream of Red Mansions" handed down from my family! Some people believe it. In the past ten years, such low-level rumors have not disappeared, but they have captured a bunch of hardcore fans, and they have created new tricks from the development of the media and won 100,000+. This communication phenomenon itself deserves attention.
Who is continuing this rude rumor? The answer may be ourselves.
The key to self-media communication based on social attributes lies in the fission of users, and the more shocking the content, the easier it is to achieve viral communication through user sharing, and the form of communication itself has nothing to do with the authenticity of the content. The "nipple music" of network information makes us happy to spread more bizarre information "free".
The information field is increasingly filled with headline parties and low-level rumors, which is punishing our laziness and impulsiveness. We don’t read the full text, but we want to forward bizarre news and get praise from friends. We clearly know that this expression is extreme and ridiculous, but we are happy to join in this excitement. This is a typical "silent spiral". When you see a sensational content, you are eager to forward it, or even don’t look at the forwarded content at all. Is it irrelevant?
For example, a few days ago, the article "14 bureau-level leaders of China Welfare Lottery Distribution Center embezzled 136 billion yuan" was screened. However, the article was accompanied by confession videos of relevant officials released by CPC Central Commission for Discipline Inspection, which did not mention the figure of 136 billion yuan at all, and other channels did not talk about this figure. For another example, the "one kilometer of expressway will charge one yuan in the future" which was screened two days ago is also a typical title party, and there is no such content in the text.
If we spend 1% of the forwarding impulse on reading the full text of the article to be forwarded, our circle of friends will probably be much cleaner. Rumors such as "Wu’s Stone Story" can be "refined" in 10 years, which is actually the vanity and greed of the devil when he uses us to spread from the media.
You will find that communication is becoming more and more convenient and efficient, but the cost of information fraud is getting lower and lower, even as Suzhou Zoo dug up an old version of A Dream of Red Mansions, without a live photo of PS; Netizens with junior high school education "edited" a "Stone Story" without providing a photo to prove that it is an old manuscript at home.
When we watch mobile phone videos, we have to double or even five times fast forward, and the greed for information curiosity has just become the demon of widespread rumors. Once upon a time, I was slow, and I could only write a Dream of Red Mansions in my life. Now, you can turn 10 rumors and 100,000+in one morning.
Reporting/feedback

The weather turned cold in October, but these rumors continued to heat up.

　　October has passed, and 2020 is coming to an end, but all kinds of rumors do not seem to stop: this winter will be the coldest winter in 60 years, eating soaked food will cause poisoning, infusion can prevent stroke, milk tea contains a lot of trans fatty acids, and fruits are sweet because of the addition of cyclamate … … Are these rumors true or false?

　　Myth 1: This winter will be the coldest winter in 60 years.

　　During the National Day this year, the temperature dropped significantly in many places in China, with some areas in the central and eastern regions dropping more than 12 degrees Celsius, and snowfall occurred in scenic spots such as Laojun Mountain and Baiyun Mountain in Henan Province. The circle of friends began to spread: "This winter will be the coldest winter in 60 years", "This year will be the coldest year since 2008" and "All this is related to La Nina".

　　Truth: Whether it will be cold or warm this winter needs to be comprehensively judged on the basis of scientific analysis, not by several snowfalls.

　　Zhai Yu, a meteorologist of China Meteorological Bureau, explained that La Nina refers to the phenomenon of large-scale continuous abnormal cooling of seawater in the eastern and central equatorial Pacific Ocean. When the duration of the phenomenon of low temperature reaches a certain level, we call it a La Nina event.

　　"Whether it’s cold winter or warm winter, there are advantages and disadvantages. For example, warm winter is conducive to the survival of bacteria and viruses in the air, which increases our chances of getting sick. Moreover, due to the high temperature, the probability of snowfall is greatly reduced, resulting in exceptionally dry weather. At the same time, eggs in the soil are more prone to overwintering reproduction, or lead to large-scale insect disasters, which is not conducive to agricultural production. However, because the temperature is not so cold, our heating demand will be relatively reduced, which is conducive to saving energy. " Yu Yu said.

　　Zhai Yu introduced that in winter, patients with cardiovascular and cerebrovascular diseases or hypertension, especially when the temperature drops suddenly or is particularly cold, the incidence rate will increase greatly. Therefore, it is necessary to pay special attention to the health problems of these elderly people during the cold winter.

　　Myth 2: Eating soaked food can cause poisoning.

　　Recently, the poisoning incident of "Sour Soup" occurred, which made rice yeast acid, a thing that people were not familiar with, frequently appear in public view. Therefore, many people began to worry about the safety of all kinds of soaked foods and refused all soaked foods for fear of being recruited.

　　Truth: Not all soaked foods contain mycotic acid, so there is no need to refuse all soaked foods. For some foods that may produce rice fermentation acid, as long as the soaking time is reasonable, poisoning can be avoided without excessive worry.

　　Xue Qingxin, a public nutritionist, said that the following foods are likely to produce rice yeast acid, and it is very important to soak and eat them reasonably in order to avoid poisoning. It is suggested that the soaking time of auricularia auricula should not exceed 4 hours and the water temperature should not exceed 30 degrees Celsius. Experiments show that the edge of auricularia auricula will crack after soaking for more than 6 hours, which not only seriously affects the quality of auricularia auricula, but also makes auricularia auricula more susceptible to microbial pollution.

　　The soaking time of river noodles and rice noodles in hot water should not exceed 20 minutes, and they should be boiled in boiling water for 1 to 2 minutes before eating. If it’s too much trouble, you can soak in cold water directly, then you have to soak for 4 hours.

　　Myth 3: Infusion can prevent stroke.

　　Many middle-aged and elderly people think that when the seasons alternate, going to the hospital for infusion can open blood vessels. As a result, many people go to the hospital for infusion as soon as winter comes, hoping to prevent cardiovascular and cerebrovascular diseases and stroke.

　　Truth: Chen Fei, an attending physician in the Department of Neurology, xuanwu hospital, Capital Medical University, said that stroke is a common name for acute cerebrovascular disease, and some people think that it can prevent cerebrovascular disease by infusing blood vessels every year, which is wrong.

　　Acute cerebrovascular diseases, including ischemic cerebrovascular diseases and cerebral hemorrhage. Head and neck vascular atherosclerosis, vascular stenosis occlusion or atrial fibrillation can all lead to ischemic cerebrovascular disease, and cerebral hemorrhage is caused by cerebral vascular rupture.

　　Most of the drugs that these middle-aged and elderly people go to the hospital are Chinese patent medicines with the function of "promoting blood circulation", which has no effect on controlling vascular stenosis and thrombosis. In addition, the "blood-activating" effect of infusion is also very short-lived, so stopping infusion will have no effect, and we can’t infuse every day.

　　So, how can we prevent cerebrovascular disease?

　　First of all, it is necessary to control the risk factors of stroke, including hypertension, diabetes, hyperlipidemia, hyperhomocysteinemia and other diseases, as well as bad living habits such as smoking, drinking, obesity and inactivity. Only by comprehensively controlling these risk factors can we prevent stroke and reduce the risk of stroke.

　　Secondly, middle-aged and elderly people should be screened for stroke regularly, and whether there is stenosis of cervical blood vessels and cerebral blood vessels can be determined by ultrasound examination, and whether there is atrial fibrillation can be determined by electrocardiogram.

　　Doctors will make prevention plans for patients according to the results of stroke screening. This plan includes establishing good living habits and making reasonable dietary adjustments. At the same time, patients should take corresponding preventive drugs according to the doctor’s advice, including antiplatelet drugs and statins.

　　Myth 4: Milk tea contains a lot of trans fatty acids.

　　"The first cup of milk tea in early autumn" became popular, and a saying began to go crazy in the circle of friends: milk tea contains a lot of trans fatty acids, which is ruining the health of young people in China.

　　Truth: Any behavior of "talking about toxicity without measurement" is unscientific. The harm of trans fatty acids to health is the result of long-term accumulation. As long as you don’t eat more, the impact on health is controllable. The key is to control the amount.

　　Shen Yingjian, deputy chief physician of the Nutrition Department of the General Hospital of Jihua Group, said that trans fatty acids are the main reason why milk tea is criticized. According to media reports, trans fatty acids can be divided into natural and artificial according to their sources. What we usually call trans fatty acids refers to artificial trans fatty acids.

　　At present, people have some misunderstandings about trans fatty acids. In fact, trans fatty acids are not illegal additives or food additives, but a derivative produced by food enterprises when they produce partially hydrogenated fats. When hydrogenated fats are used as raw materials or auxiliary materials to produce food, trans fatty acids will be contained in the products.

　　Shen Yingjian said that the harm of trans fatty acids to health depends on how much you eat. The World Health Organization (WHO) suggested in 2003 that the energy supply ratio of human trans fatty acids should be lower than 1%. The report on dietary intake level and risk assessment of trans fatty acids among residents in China released in 2013 shows that the energy supply ratio of trans fatty acids consumed by residents in China is only 0.16%. In big cities like Beijing and Guangzhou, the energy supply ratio of trans fatty acids among residents is only 0.34%, and only 0.4% of urban residents’ intake exceeds the recommended value of the World Health Organization. In other words, most people’s daily intake of trans fatty acids does not exceed the recommended standard.

　　Myth 5: Melon fragrance is due to injection of sodium cyclamate.

　　The loveliness of autumn, in addition to the crisp autumn air, also has the fragrance of fruits and vegetables. However, many people have found that the fruit now seems to be sweeter than the fruit 10 years ago. There are even rumors recently that this is because fruit farmers inject cyclamate into the fruit to increase the sweetness in order to make the fruit sell at a good price. Is it true?/You don’t say.

　　Truth: Sodium cyclamate is a non-nutritive sweetener and an international food additive. It is cheap, which is 1/3 of the price of sucrose, but its sweetness is 30 to 40 times that of sucrose, so it is widely used in the processing fields of drinks, desserts, juices and other foods.

　　First of all, it should be clear that the use of sodium cyclamate will not affect our health as long as it is within the prescribed scope; Secondly, it is unlikely that "fruit farmers add cyclamate to their fruits to optimize their taste". Why?

　　You know, beating sodium cyclamate on the surface of fruit will not have any effect on the sweetness of fruit at all. This is because sodium cyclamate is soluble in water but insoluble in oil. Even if sodium cyclamate is sprayed on the surface of fruit, sodium cyclamate will not enter the interior of fruit, so there is no possibility of increasing sweetness.

　　If vendors want to sweeten the fruit by injection, they need to inject the fruit in all directions, not to mention the time-consuming and laborious operation itself, which will destroy the cell wall of the fruit and accelerate the decay of the fruit. In other words, for fruit farmers and fruit vendors, it is harmful to inject cyclamate into fruits at any link.

　　Since there is no injection of sodium cyclamate, why is the fruit getting sweeter and sweeter?

　　There are sucrose, glucose and fructose in fruits, among which fructose has the highest sweetness, followed by sucrose and glucose. In different fruits, the contents of these three components are different. For example, apples are mainly fructose, peaches and sugarcane are mainly sucrose, and the variety and quantity of sugar in fruits determine the difference in taste of different fruits.

　　In addition, the sweetness of fruit has a great relationship with the quality of plant leaves. Because the leaves of plants are "organs" that perform photosynthesis, its important task is to produce glucose, carbohydrates, various organic acids and other substances in photosynthesis. The more efficient leaves a plant has in the growth stage, the more nutrients it produces, the higher the efficiency of storing nutrients in the tree, and the corresponding improvement of fruit quality.

　　With the continuous breakthrough and innovative development of planting science, the favorable conditions for plant growth have been improved and guaranteed in a more comprehensive way, and the quality and taste of fruit have naturally been improved.

Innovating ＂Tea Forest and Fruit＂ Compound Management in Liping County to Release the Benefits of Family Farms

In recent years, Liping County has focused on the cultivation of new agricultural business entities, taking Tianyi Family Farm in Gaotun Street as a model, innovating the "tea and fruit forest" compound business model, supporting infrastructure, implementing variety interplanting and adjusting business methods, effectively solving the problems of extensive farm management, single model and low efficiency, and boosting industrial upgrading and efficiency.
First, supporting infrastructure to solve the problem of extensive management. According to the needs of seasonal harvesting, new sidewalks, water supply pools, aqueducts, sheds, workshops, leisure farms and other facilities will be built in the park to improve the level of farm management and protection, effectively manage and protect the tea trees planted in the park, reduce operating losses, and lay a solid foundation for the compound planting of "tea and fruit forests". At present, 6 kilometers of production access road, 600 cubic meters of irrigation pool and 4 kilometers of irrigation aqueduct have been built in the tea garden, which basically meets the needs of compound planting.
Second, interplanting forest and fruit trees to solve the problem of single business model. Explore the implementation of the "tea forest fruit" compound management model, make use of the biological characteristics of tea trees and the principle of symbiosis with other economic tree species, interplant the forest fruit varieties such as Taxus chinensis, camellia oleifera, blueberry and Myrica rubra between tea terraces and the edge of tea garden, improve the land utilization rate, enrich the tea garden ecosystem, improve the tea quality, achieve harvest all year round, and promote the "double growth" of agricultural output and labor demand. At present, the annual output of dry tea on the farm is more than 50 tons, and there are more than 10 kinds of forest and fruit trees, which has driven more than 500 farmers around to achieve employment at home, and the average household income has increased by more than 3,000 yuan.
The third is to strengthen the cultivation of the main body and solve the problem of low management level. Encourage and guide multi-enterprise cooperation and promote resource sharing and technology sharing. At the same time, by providing technical guidance, tea green purchase, processing and sales and other services in the whole industry chain, the farm drives the masses to grow tea, achieving a win-win situation for enterprises and farmers. Up to now, there are more than 10 cooperative tea enterprises between surrounding tea enterprises and Tianyi Family Farm, involving more than 3,000 mu of tea garden area; Drive 38 tea farmers to plant 278 mu of tea, and the annual income of the masses reaches more than 830,000 yuan.
The fourth is the integration and development of tea tourism to solve the problem of low operating efficiency. Relying on the resource advantages of "tea and fruit forest" garden, we will build a recreational tourism and leisure sightseeing experience park, and develop formats such as garden viewing, tea and fruit picking, and processing experience of special agricultural products, so as to promote the integrated development of tea tourism, release consumption potential and stimulate the vitality of family farms. Since 2023, Tianyi Farm has received more than 4,000 tourists and earned more than 50,000 yuan. (Liping County People’s Government Network)
Reporting/feedback